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Though rarely fatal, skin diseases are known to be associated with increased psychiatric morbidity and 
considerable impairment of quality of life (QoL). Health Related Quality of Life (HRQoL) in skin 
diseases can be assessed by generic or skin speciﬁc instruments. One hundred sixty patients with a 
range of dermatological diagnoses were studied on a cross sectional observational paradigm. Skindex-
29, a skin speciﬁc instrument, was used to assess QoL, while anxiety and depression were assessed by 
Anxiety Status Inventory (ASI) and Depression Status Inventory (DSI), respectively.  Sixty two 
patients (39%) had impaired QoL out of which 37(60%) had severe impairment. 11 patients (7%) had 
anxiety and 22(14%) had depression in the mild to moderate range.  Gender, anxiety, depression and 
effect on appearance seem to be not related to impaired QoL. Further large scale studies are needed to 
ascertain the factors impinging on the QoL of dermatologically ill patients. 
Keywords: Quality of life, anxiety, depression, skindex-29, skin diseases.
ABSTRACT
Introduction
 Skin gets frequently damaged because it is 
directly in the 'ﬁring line'. The 3000 and odd 
known diseases of skin form the most common 
health problems afﬂicting people worldwide (1). 
Some of these conditions are among the top ten 
leading causes of non-fatal disease burden (2). 
Though rarely life threatening, the effects of 
cutaneous disorders on patients' lives can be 
profound as in addition to the distress  brought 
about by symptoms and lesions, they affect 
interpersonal interactions as the lesions as well 
as the treatment thereof  affect the appearance of 
individuals (3). Prevalence of psychiatric 
disorders in dermatological patients is higher 
than that of certain medical conditions like 
cancer, cardiac and neurological disorders (4) 
but remain unrecognized and underestimated (5, 
6). The interrelationships between skin and 
psychiatric disorders can be quite complex: 
Social isolation and stigma associated with skin 
conditions may result in psychiatric illnesses; 
poor hygiene in chronic psychiatric disorders 
can cause skin problems; psychiatric disorders 
may present as dermatological problems, 
( D e l u s i o n a l  p a r a s i t o s i s ,  b o d y 
dysmorphophobia) certain drugs used in 
dermatology may have secondary psychiatric 
problems and vice versa; psychiatric disorders 
may aggravate skin conditions and also may lead 
to poor help seeking behavior (7-9). Psychiatric 
morbidity in skin diseases therefore may 
adversely affect quality of life (QoL) in many 
ways. 
 Health-related quality of life (HRQoL), 
deﬁned as the patients subjective evaluation of 
the inﬂuences of their current health status on 
their ability to achieve and maintain a level of 
overall functioning that allow them to achieve 
valued life goals and that are reﬂected in their 
general wellbeing (10),  is considered as an 
essential outcome measure in addition to clinical 
parameters in skin diseases (11, 12).  Upto a 
third of persons with skin diseases are known to 
suffer from psychopathology mainly in the form 
of anxiety and depression (13-16) but due to 
shortfall of required skills dermatologist's 
assessment of mental status of patients is known 
to be sensitive at 30% only (5) which 
underscores the importance of collaborative 
management of patients by dermatologists as 
well as psychiatrists. However, it would be 
wrong to assume that QoL is totally linked to 
psychiatric morbidity (17).  
 Psychiatric morbidity and HRQoL are 
f a i r l y  w e l l  i n v e s t i g a t e d  i n  s p e c i ﬁ c 
dermatological conditions like Psoriasis (18, 
19), Vitiligo (20, 21), Acne (22, 23), Alopecia 
(24, 25), Eczema (26) and Hansen's disease (27).  
There are just a few studies which investigated 
psychia t r ic  morbid i ty  and  HRQoL in 
dermatological patients in general (8, 28-30). 
Somehow this ﬁeld did not appear to have 
attracted investigators from India; two recent 
reviews from India hardly had any references of 
Indian studies (4, 17).  
Material and Method
 The study was conducted at a hospital 
attached to a medical college in central India on a 
cross sectional observational design. One 
hundred and sixty patients were selected at 
random from in-patient and outpatient 
population of the dermatology department. All 
the patients who were above 18 years of age and 
those who were willing to participate in the study 
only were accepted. Patients suffering from 
major medical illnesses, psychoses and 
signiﬁcant cognitive impairments were 
excluded from the study.  All the patients were 
furnished with written information about the 
nature of the study. The study was approved by 
the research and ethics committee of the 
institution. 
 All the skin diagnoses were made by 
dermatologists. Every patient was subjected to 
standard mental status examination. The 
following instruments were used to measure 
anxiety, depression and QoL :
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Anxiety Status Inventory (ASI): This is a 
structured interview version of Zung's self-
rating anxiety scale (31).  20 affective and 
somatic symptoms associated with anxiety are 
rated on a 4 point Likert scale (none, mild, 
moderate and severe). Maximum score is 80. 
Obtained score is converted into an index and 
graded into mild, moderate and severe. The test 
was translated into vernacular Hindi by 
translation and back translation by different 
experts and administered to 50 bilinguals. The 
correlation between English and Hindi version 
was found to good (r=0.76, p<0.001). The Hindi 
version was utilized for the study.  
Depression Status Inventory (DSI): This is a 
structured interview version of the Zung Self 
Rating Depression Scale (32). There are 20 items 
in this scale that explore the affective, 
psychological and somatic symptoms associated 
with depression. Each question is scored on a 
scale of 1 to 4. Maximum possible score is 80.  
Procedure similar to anxiety inventory was 
adapted to obtain Hindi version and correlation 
was found to be good (r=0.79, p < 0.01). 
Obtained score in a given individual is converted 
into an index and graded into mild, moderate and 
severe grades.
  
Skindex-29: This is a skin speciﬁc QoL 
instrument devised by Chren (33).  It has 30 
items distributed into domains (symptoms, 
function and emotion). Each of the items is 
scaled on a 5 point Likert scale.  All the 
responses are transferred to a linear scale 
(Never=0, rarely=25, sometimes=50, often=75 
and all the time =100).  Domain and overall 
scores can be computed. Overall score is the 
mean of the responses. Item number 18 is 
excluded from scoring as per the guidelines of 
the originators of the test. This test was also 
subjected to translation and back translation.  
Hindi version was found to be well correlated to 
the original English version ( r=0.86, p< 0.001).  
QoL scores were graded into mild, moderate and 
severe grades as per Prinsen et al (34).
Statistical Analysis: Depression and anxiety 
scores were correlated with overall Skindex-29 
scores by means of Pearson's product moment 
correlation test. Mean anxiety and depression 
scores of each grade of Skindex-29 were 
compared by means of one-way ANOVA 
followed by post hoc Tukey's test.  One-way 
ANOVA was also used to compare the anxiety, 
depression and QoL scores in relation to 
symptom and diagnostic categories. Student's     
t-test was used to compare the anxiety, 
depression and Skindex-29 scores between 
genders. Domain scores were not subjected to 
analysis in this study.
Results
 A total of 62 patients (39%) had impaired 
QoL out of which 15 had mild, 10 had moderate 
and 37 had severe grades impairments. Ninty 
eight patients reported no impairment in their 
QoL. Twenty two patients (14%) had depression 
while 11 (7%) had anxiety.  Mean overall 
Skindex score was 25.27±20.21 (Mean±SD) 
while that of anxiety and depression was 
32.3±8.43 and 39± 8.4, respectively. There was 
no signiﬁcant difference (t 0.39, p<0.05) 
between Skindex scores of males (26.1±20.38) 
and females (24.51±20.22). No signiﬁcant 
difference was also found in the anxiety (t 0.37, 
p<0.05), depression (t 0.12, p<0.05) between 
genders.  Overall Skindex-29 scores were found 
to be highly correlated to ASI (r= 0.29, p< 0.001) 
and DSI scores (r=0.37, p<0.001). We 
categorized patients into seven groups based on 
the predominant symptoms that they had, and 
compared their anxiety, depression and Skindex-
29 scores. No signiﬁcant differences in anxiety 
(F 1.09, p>0.05) depression (F 0.71, p>0.05) and 
Skindex scores ( F 1.22, p>0.05) were found 
between patients with different symptoms 
(Table 1) .   ANOVA revealed uniform 
distribution of anxiety (F 1.69, p>0.05) and 
depression (F 1.02, p>0.05) scores across 
diagnostic categories. However, Skindex-29 
scores were found to be differentially distributed 
( F 2.69, p< 0.007) in various diagnoses: scabies 
patients had the lowest score (mean 13.8,  SD 
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ANOVA Anxiety F=1.09     Df = 6,153  P=0.366
ANOVA Depression  F= 0.71    Df = 6,153    P=0.642
ANOVA QOL           F=1.22     Df = 6,153     P=0.298
Table 1: Anxiety, Depression, Skindex-29 QoL scores in-relation to Symptoms
Symptoms
 
Anxiety
 
Depression
 
Skindex-29
 
Eruptions 
 
(n=45)
 26.6
 
(7.4)
 31.6
 
(6.2)
 24.9
 
(18.5)
 
Erythema 
 
(n=37)
 
27.1
 
(9.1)
 
33.4
 
(9.5)
 
27
 
(17.1)
 
Hyperpigmentation  
(n=32) 
26.7 
(8.2) 
31.8  
(6.5)  
24.3  
(21.1)  
Hypopigmentation 
(n=20) 
25.3 
(7.2) 
30.6  
(5.9)  
22.1  
(18)  
Itching 
(n=13)
 
21.8 
(2.1)
 
29.3  
(1.8)
 
22  
(17)
 
Impaired Sensation 
 
(n=5)
 
30.4
 
(9.4)
 
31.8
 
(3.3)
 
45.2
 
(22)
 
Alopecia
 (n=8)
 
23
 (4.85)
 
30
 (20)
 
29.8
 (1.8)
 
Diagnosis
 
N
 
Anxiety
 
Depression
 
Skindex-29
 
Acne
 
38 
 
(23.7)
 29.9
  
(8.2)
 32.2
  
(7.1)
 26
  
(20.2)
 
Eczema
 
29
 
(18.1)
 
25.8
  
(6.2)
 
32.3
  
(5.6)
 
33
  
(19.8)
 
Tinea
 
27
 
(16.8)
 
28.4
 
 
(7.3)
 
32.6
  
(3.5)
 
27.6
  
(20.1)
 
Hansen
disease 
 4 
(2.5) 
31.2  
(10.9) 
32   
(3.8)  
45.8   
(25)  
Psoriasis 17 
(10.6) 
30.7  
(13.9) 
34.6   
(13)  
38   
(21.1)  
Scabies 20 
(12.5)
 
23  
(3.2)
 
30   
(2.3)
 
13.8   
(9.9)
 
Vitiligo
 
6 
 
(3.75)
 
22.1
  
(3.4)
 
26.1
  
(4.3)
 
16.1
  
(4.2)
 
Alopecia
 
8
 (5)
 
23
 
 
(4.8)
 
30
 
 
(2)
 
29.8
 
 
(1.8)
 Urticaria
 
11
 (6.8)
 
22.3
  (3.4)
 
30.4
  (4.1)
 
21.7
  (16)
 
Table 2 : Anxiety, Depression, Skindex-29 QoL scores in-relation to Diagnosis
ANOVA Anxiety F=1.69   Df = 8,151     P=0.099 NS 
ANOVA Depression F= 1.02   Df =8,151      P=0.429 NS
ANOVA QOL          F= 2.69   Df =8,151      P=0.007 (Sig.)
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Normal  
(N=98) 
Mild  
(N=15) 
Moderate  
(N=10)  
Severe  
(N=37)  
Mean 28.1 31.5 32.8  38.4  
SD 7.9 5.7 8.7  14.3  
Table 3 : Skindex vs ASI
F:4.69            P<0.05         Df: 3,156
Tukeys Test
Normal vs mild      t=1.11       P>0.05 (NS)
Mild vs moderate  t=0.15        P>0.05 (NS)
Moderate vs severe    t=1.53        P>0.05 (NS)
9.8) while people with Hansen's disease had the 
highest impairment (mean 45.8, SD 25.0) (Table 
2).  Anxiety scores of patients with various 
grades of impairment of QoL though found to be 
non- homogenous ( F 4.69, p <0.05) but multiple 
comparisons by Tukey's test revealed no 
signiﬁcant differences (Table 3).  Depression 
scores of patients with different grades of QoL 
impairments were also found to be not uniform 
(F 4.37, p <0.05 ) but post hoc analysis by 
Tukey's test  revealed no signiﬁcant differences  
(Table 4).
Discussion
 The interaction of dermatological 
conditions on the psychosocial aspects of 
existence can be quite complex with matters 
impinging on such issues as satisfaction with 
appearance, body image, identity, socialization 
and sexuality with potential for restricted social 
interactions, reduced opportunities for 
employment (35, 29) and the obvious threat of, 
and sometimes actual, diminished opportunities 
for interpersonal attraction, friendship and mate 
selection. Clinicians routinely interpret 
measurements of physical functioning clinically 
and by investigations. Interpretations of the 
ﬁndings, in most medical illnesses, is fairly 
simple as they are compared against norms but in 
cases of skin disease due to intervening 
emotional factors, patient's experience with 
illnesses becomes a crucial factor in determining 
effectiveness of treatment (11).  Suffering could 
be unique in many ways in skin conditions.
 We attempted to assess QoL in a large 
sample of dermatologically ill by means of 
Skindex-29 which is considered to be an ideal 
tool for such an investigation (36).  We analyzed 
only the overall scores in the present paper. We 
also attempted to ﬁnd if the grades of severity of 
HRQoL correspond in any way to the grades of 
anxiety and depression measured by standard 
instruments. We believe this is the ﬁrst time that 
such an investigation was carried out in India.
 In the present study, we found more than a 
third of patients had reported impaired QoL, 
majority (60%) of which to a severe degree. 
HRQoL is a subjective estimate. Wide variations 
in scores are therefore possible as disease 
perceptions may vary from individual to 
individual and culture to culture. Skindex-29 
scores ranging from 20 to 78 have been reported 
in literature (18, 29, 37-39).
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Normal  
(N=98) 
Mild  
(N=15) 
Moderate  
(N=10)  
Severe  
(N=37)  
Mean 36.5 39.0 39.5  43.9  
SD 5.7 5.8 12.3  12.2  
Table 4 : Skindex vs DSI
F: 4.37     P<0.05         Df: 3,156
Tukeys Test
Normal vs mild          t=1.27       P>0.05 (NS)
Mild vs moderate       t=0.33        P>0.05 (NS)
Moderate vs severe     t=1.62        P>0.05 (NS)
 The widely dispersed scores indicate 
differential effects but were not related to 
s y m p t o m s  w h i c h  w e  ﬁ n d  s o m e w h a t 
counterintuitive as we imagined symptoms like 
pain, lack of pain, hyperpigmentation and 
hypopigmentation eruptions and so on will have 
different implications for the patients. Patients 
with different symptoms appear to be uniformly 
distressed  (Table  1).  The diagnostic label of the 
disease and chronicity seem to be signiﬁcant 
determining factors as we found conditions like 
Hansens and psoriasis are associated with poor 
QoL in contrast to scabies, ﬁndings are in 
agreement with Kosaraju et al (40), Sanclemente  
et al  (41).  Effect of the disease lesions on 
appearance do not seem to be affecting the QoL 
much as we ﬁnd obviously visible conditions 
like acne, vitiligo, tinea and urticaria are 
associated with fairly good QoL (Table 2).  This 
ﬁnding, once again, is contrary to what is 
expected; perhaps analysis of domain scores will 
throw some light on this phenomenon.
 In the present study, the prevalence of 
anxiety was found to be much less than that 
reported by Seyhan et al (8) (13.4%), Kumar et 
al (19) (52%), Jindal et al (42) (11.28%) and 
Aslam et al (43) (20%), Abebe et al (44) 
(37.4%). It is to be noted that they investigated 
individual skin conditions. Our study sample 
included all major and minor conditions hence it 
is possible the prevalence ﬁgures are getting 
averaged. We found signiﬁcant correlation 
between anxiety scores and Skindex scores 
(r=0.29, p <0.001).  Other investigators reported 
similar results (45-47).  Though signiﬁcant, 
anxiety is found to be contributing to only 8% of 
the variance of HRQoL. Further, we tried to 
assess if different grades of anxiety correspond 
to similar grades of impairment of HRQoL as 
reﬂected in Skindex grades. On the face of it 
A N O VA g i v e s  f a l s e  i m p r e s s i o n  o f 
correspondence between anxiety and HRQoL 
scores. This is expected because the scores are 
correlated.  But multiple comparison with 
Tukey's test of the anxiety scores between 
normal and mild, mild and moderate and 
between moderate and severe grades of Skindex 
revealed no signiﬁcant difference (Table 3).
 The prevalence of depression (14%) in the 
present study also is less than that reported by 
Schmit and Ford (48) (31%), Basher et al  (49) 
(34%),  Sharma et al   (50) (46.25%), 
Ponarovsky  et al (30) (23.1%),  Seyhan et al  (8) 
(32%),  Solgajova et al (51) (37.5%). Our 
ﬁnding of signiﬁcant correlation (r 0.34, 
p<0.001) between depression scores and 
Skindex scores are similar to other studies (45-
48).  However, depression is seen to be 
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contributing to only 11% of the variance in 
Skindex-29 scores. ANOVA and posthoc 
Tukey's test analysis of depression scores of 
different grades of Skindex scores yielded 
results similar to anxiety scores (Table 4).  It 
appears depression and anxiety scores cannot 
serve as anchors to determine grades of severity 
of impairment of QoL.
Conclusion
 The present study raises the familiar 
difﬁculty in interpreting HRQoL scores in 
patients with skin diseases (34, 52). The anchor 
based categories of Prinsen et al (34) may not 
serve the purpose in our settings. It also appears 
that skin diseases have different meanings to 
Indian patients than what is generally perceived. 
An anchor-based approach with appropriately 
worded anchor questions as well as a distribution 
based method Nijsten et al (53) with an 
additional normal sample may help in 
determining the grades of impairment of QoL. 
The cross sectional nature of the present study 
does not allow any inferences to be drawn about 
the responsivity of the scores to treatment. All 
categories of skin diseases are also not 
represented in adequate numbers in the present 
study. More importantly, what are the factors 
that have unique inﬂuence in determining QoL 
of dermatologically ill in our setting need to be 
explored fully to enable clinicians to chalk out 
appropriate strategies collaboratively to deliver 
comprehensive and holistic care to the clientele.           
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